Peer-reviewed veterinary case report
Combination chemotherapy with mitoxantrone and cyclophosphamide
By Henry, C J et al.·Published in Journal of the American Animal Hospital Association·1999·Department of Veterinary Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies.
- Species:
- dog
Plain-English summary
Thirteen dogs with confirmed cancer were treated with a combination of two chemotherapy drugs, mitoxantrone and cyclophosphamide, given in one to four doses every three weeks. To help support their immune systems during treatment, they also received a medication to boost white blood cell production. While the treatment was found to be safe for the dogs, it did not show a clear benefit over using mitoxantrone alone in shrinking tumors.
People also search for: dog cancer treatment options · mitoxantrone for dogs · chemotherapy side effects in dogs
Abstract
Thirteen dogs with histopathologically confirmed malignancies were treated with mitoxantrone and cyclophosphamide combination therapy. One to four doses were administered at 21-day intervals. Recombinant human granulocyte colony-stimulating factor was administered to ameliorate myelosuppression in dogs with neutrophil nadirs less than 1,000/microl. While the protocol appears to be safe for use in tumor-bearing dogs, an advantage over mitoxantrone single-agent protocols in terms of tumor response was not demonstrated in this initial pilot study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/10333263/